Please assess the completion status of the following clinical trial:

Trial Title: 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Open-angle glaucoma patients (primary open-angle glaucoma, exfoliative, or pigmentary glaucoma) insufficiently controlled on branded, or generic latanoprost monotherapy (IOP \> 20 mm Hg as determined by 2 separate IOP measurements at 10:00 ± 1 hour)~* Patients with signs, or symptoms of ocular surface disease.~* Only those open-angle glaucoma subjects who, according to the opinion of the principal investigator, require further IOP reduction.~* Patients must have demonstrated at least 20% IOP reduction at 10:00 (± 1 hour) and who are treated with branded, or generic latanoprost monotherapy for at least 3 months.~* Only subjects with open-angle glaucoma that have exhibited (prior to latanoprost therapy) untreated, sitting IOP evaluated with Goldmann tonometry between 25-39 mm Hg at 10:00 (± 1 hour).~* Age between 21-85 years~* Mild to moderate glaucomatous disc damage and visual field loss (less than -12 dB mean deviation visual field loss attributed to glaucoma~* Those with 0.8 or better vertical cup-to-disc ratio and visual acuity greater than 0.1 in the study eye.~* Open anterior chamber angles.~* Those who have to demonstrate a reliable visual field (at least two visual fields with less than 20% fixation losses, false positives, or negatives)~* Patients who understand study instructions, are willing to attend all follow-up appointments and will comply with study medication usage.~Exclusion criteria~* Patients with a history of less than 10% IOP decrease on any IOP-lowering medication.~* Those with evidence of concurrent conjunctivitis, keratitis, or uveitis in either eye.~* Subjects with a history of inadequate adherence; intolerance, or contraindication to either prostaglandins, β-blockers, dorzolamide, or benzalconium chloride (BAK)~* Patients with severe ocular surface disease, previous intraocular conventional or laser surgery in the study eye (within 6 months prior to enrolment); previous history of ocular trauma; use of corticosteroids (within 3 months before the enrolment) and use of contact lenses.~* Those that on baseline examination show clinical evidence of inflammation, signs of ocular infection (except blepharitis), signs of any corneal abnormality that will affect subsequent IOP measurements~* Subjects that show unwillingness to participate in the trial.~* Females of childbearing potential or lactating mothers.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Tafluprost drops (Type: ACTIVE_COMPARATOR): Treatment with preservative-free talfuprost drops administered once in the evening. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
- Tafluprost and dorzolamide/timolol drops (Type: ACTIVE_COMPARATOR): Concomitant therapy with preservative-free talfuprost drops administered once in the evening and dorzolamide/timolol fixed combination drops given twice daily. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).